Amifostine-Induced Fever: Case Report and Review of the Literature

Pharmacotherapy

Volumn 24, Issue 1, 2004, Pages 155-158

  Boehme, Sabrina ^a   Wilson, David B ^a,b  

^a St Luke's Boise Regional Medical Center   (United States)

^b St Luke's Mountain States Tumor Institute   (United States)

Author keywords

Amifostine; Fever; Fever rash syndrome

Indexed keywords

AMIFOSTINE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CELL PROTECTION; CHILL; FEVER; FLUSHING; HUMAN; HYPOCALCEMIA; HYPOTENSION; LOW DRUG DOSE; MALAISE; MALE; NEUTROPENIA; RADIATION PROTECTION; SEPSIS; SNEEZING; SOMNOLENCE; TASTE DISORDER; VOMITING; XEROSTOMIA;

AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEVER; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PRODRUGS; RADIATION-PROTECTIVE AGENTS; XEROSTOMIA;

EID: 0347357811     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.1.155.34799     Document Type: Article

References (19)

1. Brueggmann J, Cass Y. Amifostine. In: Drugdex system. Greenwood Village, CO: Micromedex Healthcare Series, vol 115. Expires March 2003.
2. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/ or chemotherapy. Cancer Clin Trials 1980;3:211-16.
3. Medimmune Oncology, Inc. Ethyol (amifostine) product information. Bedford, OH; October 2001.
4. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000; 18(10):2226-33.
5. Tahsildar HI, Biaglow JE, Klingerman MM, Varnes ME. Factors influencing the oxidation of the radioprotector WR-1065. Radiat Res 1988;113:243-51.
6. Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995;50(6):1001-31.
7. Murray D, Prager A, Meyn Rf, et al. Radioprotective agents as modulators of cell and tissue radiosensitivity. Cancer Bull 1992;44:137-44.
8. Durand RF. Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br J Cancer 1983;47:387-92.
9. Smouk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Radiat Res 1988;48:3641-7.
10. Constine LS, Zagars G, Rubin P, Klingerman MM. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986;12:1505-8.
11. Liu T, Liu Y, He S, Zhang Z, Klingerman MM. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69:2820-5.
12. Niibe H, Takahashi I, Mitsuhashi N, et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. Nippon Gan Chiryo Gakkai Shi 1985;20:981-93.
13. Klingerman MM, Turrisi AT, Urtasun RC, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988;14: 1119-22.
14. Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-amino-propylamino)ethylphosphorothioic acid]. Cancer Treat Rep 1986;70:1389-93.
15. Buresh CM, Baker KS, Shafer M. Fever and rash after amifostine therapy. J Pediatr Hematol Oncol 1998; 201(4):361-2.
16. Shaw PJ, Bleakley. Systemic inflammatory response syndrome associated with amifostine. Med Pediatr Oncol 2002;34: 309-10.
17. Klingerman MM, Glover DJ, Turrisi AT, et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984;10:1773-6.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
19. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.